Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma

Published:2024-05-01 Issue:5 Volume:10 Page:674
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Sun Ryan¹,Moraleda Jose M.²,Wei Lee-Jen³

Affiliation:

1. Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston

2. Hematology and Advanced Therapies Department, University Hospital Virgen de la Arrixaca, Murcia, Spain

3. Department of Biostatistics, Harvard University, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2816346/jamaoncology_sun_2024_le_240003_1715802220.79917.pdf

Reference5 articles.

1. Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial.;Qin;JAMA Oncol,2023

2. Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio.;Pak;JAMA Oncol,2017

3. Alternatives to hazard ratios for comparing the efficacy or safety of therapies in noninferiority studies.;Uno;Ann Intern Med,2015

4. Evaluating treatment effect based on duration of response for a comparative oncology study.;Huang;JAMA Oncol,2018

5. Analysis of response data for assessing treatment effects in comparative clinical studies.;Huang;Ann Intern Med,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP